CG Oncology (CGON)
Developing cretostimogene for bladder cancer alongside contract fill-and-finish manufacturing.
Something off on this page? Send us feedback.
Develops intravesical cretostimogene for high-risk and intermediate-risk non-muscle invasive bladder cancer, while controlled subsidiary Biovire earns contract fill-and-finish manufacturing revenue. No drug is approved or sold, leaving the business dependent on its sole candidate's clinical, regulatory, manufacturing, and commercialization path.
Develops cretostimogene grenadenorepvec, an intravesically delivered oncolytic immunotherapy designed to destroy tumor cells directly and activate an immune response. The sole drug candidate targets bladder cancer through BOND-003 in high-risk BCG-unresponsive non-muscle invasive disease and PIVOT-006 in intermediate-risk disease.
Extends the program through CORE-008 monotherapy and combination cohorts across high-risk settings, alongside a North American expanded-access pathway. Completed late-stage trial enrollment, published BOND-003 results, and initiated a rolling U.S. biologics license application for the initial high-risk indication.
Generates commercial revenue through controlled subsidiary Biovire, which provides fill-and-finish manufacturing services and produces cretostimogene clinical supply. No product is approved or sold; clinical progress, regulatory approval, and commercialization depend on the sole candidate, while clinical trials and parts of manufacturing and distribution still rely on third parties.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Truist Financial | Target | Target: $82 | Target: $85 |
| Jul 29, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $75 | Target: $100 |
| May 14, 2026 | Truist Financial | Target | Target: $75 | Target: $82 |
| May 11, 2026 | RBC Capital | Reiterate | Rating: —Target: $79 | Target: $81 |
| May 11, 2026 | Wedbush | Reiterate | Rating: —Target: $70 | Target: $80 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.03B · Total debt $8.8M · Total assets $1.09B · Shareholders' equity $1.03B
- Revenue
- $1.2M
- Operating income
- −$86.4M
- Net income
- −$79.1M
No dividends on record.
| Institutions | 106.57% | 94.46M shares | |
|---|---|---|---|
| 246 holders · as of Jun 30, 2026 | |||
| Insiders | 4.19% | 3.72M shares | |
| 2 holders · as of Mar 13, 2026 | |||
| Strategic holders | 16.26% | 14.41M shares | |
| 3 holders · as of Feb 14, 2025 | |||
| Adds to | 127.02% | ||
88.64M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 127.02%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
RTW Investments, LPInstitution | 9.61% | 8.51M | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 7.46% | 6.62M | as of Jun 30, 2026 |
Decheng Capital LLCInstitution | 7.19% | 6.37M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.06% | 6.26M | as of Jun 30, 2026 |
Unique Diamond Investments LimitedStrategic | 6.27% | 5.56M | filed Jul 22, 2024 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Leonard E. Post | director | −1,000 | $72.98 |
| Aug 14, 2026 | Leonard E. Post | director | −1,000 | $74.54 |
| Jul 15, 2026 | Leonard E. Post | director | −1,000 | $71.17 |
| Jul 10, 2026 | James Mulay | director | −24,165 | $75.16 |
| Jun 25, 2026 | Brian Guan-Chyun Liu | director | +371,085 | $66.87 |
- ImmunityBio
Approved intravesical IL-15 immunotherapy plus BCG in NMIBC
- Johnson & Johnson
Late-stage intravesical gemcitabine system for high-risk NMIBC
- Merck
Approved checkpoint therapy in BCG-unresponsive high-risk NMIBC
- UroGen Pharma
Approved intravesical mitomycin therapy in recurrent LG-IR NMIBC
- enGene Therapeutics
Pivotal intravesical gene-therapy program for high-risk NMIBC
- Pfizer
Phase 3 PD-1 plus BCG program in BCG-naive high-risk NMIBC
- Protara Therapeutics
Intravesical cell-based immunotherapy in BCG-unresponsive NMIBC
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CG Oncology | $76.62 | −2.08% | $6.90B | — | — | 1,108.2 | — |
| ImmunityBio | $9.06 | +7.24% | $8.85B | — | — | 53.4 | +93.9% |
| Johnson & Johnson | $268.53 | −0.35% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Merck | $151.53 | +1.36% | $369.24B | 119.6 | 17.6 | 5.6 | +5.1% |
| UroGen Pharma | $42.84 | −0.83% | $2.10B | — | 34.8 | 11.2 | +199.2% |
| enGene Therapeutics | $2.04 | +3.83% | $131.3M | — | — | — | — |
| Pfizer | $27.84 | +0.36% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Protara Therapeutics | $3.68 | +4.70% | $197.3M | — | — | — | — |
| Median | 36.7 | 20.1 | 6.6 | +6.6% |